Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated April 20, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing specifically details transactions executed under a programme initiated on February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Share Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Current Programme Phase Cap: Up to DKK 3.8 billion for the period from February 4, 2026, to May 4, 2026.
- Total Shares Repurchased (as of April 17, 2026): 12,257,992 B shares.
- Total Transaction Value: DKK 3,148,710,807.
- Average Purchase Price: DKK 256.87 per B share.
- Treasury Shares Held: 28,397,791 B shares (0.6% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the last announcement on April 13, 2026, the company executed five additional repurchase transactions between April 13 and April 17, 2026. The average purchase price for these recent transactions ranged from DKK 237.12 to DKK 259.91. The accumulated number of shares repurchased under the programme increased from 11,007,992 to 12,257,992.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period beginning February 4, 2026. The current phase targets DKK 3.8 billion by May 4, 2026.
Management Commentary: The company reiterates its purpose to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the repurchase programme under EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total programme and the DKK 3.8 billion current phase.
- Confirm the total number of treasury shares held (0.6% of share capital) and its impact on earnings per share.
- Review the average purchase price trend (DKK 256.87) against current market prices to assess execution efficiency.
- Check the company website (novonordisk.com) for daily transaction details as referenced in the filing.